Sage Therapeutics has terminated two long-suspended phase 3 zuranolone clinical trials after talks with the FDA led it to believe it can seek approval without the data. The biotech shared the update alongside news of a delay to data from another phase 3 because of slow enrollment in the pandemic.
Massachusetts-based Sage paused enrollment in its REDWOOD and RAINFOREST clinical trials in the fourth quarter of 2019 as part of the revision of its strategy in light of the failure of another study in major depressive disorder (MDD).
